Upcoming Investor Conferences Featuring Apogee Therapeutics
Apogee Therapeutics, Inc. (NASDAQ: APGE), a dynamic clinical-stage biotechnology company, is making waves in the inflammatory and immunology sectors. This innovative company is preparing to engage with investors at several key conferences in November, presenting an opportunity for stakeholders to learn more about its novel biologics aimed at treating conditions such as atopic dermatitis (AD), asthma, and chronic obstructive pulmonary disease (COPD).
Details of the Conferences
Guggenheim Inaugural Healthcare Innovation Conference
One of the most anticipated events is the Guggenheim Inaugural Healthcare Innovation Conference on November 12. During this gathering, Apogee’s management will discuss their groundbreaking approaches and insights at 3:00 PM ET.
Stifel 2024 Healthcare Conference
Following this, on November 18, Apogee will be featured at the Stifel Healthcare Conference. This event is crucial for investors to understand how Apogee's advancements can change the landscape of healthcare, with discussions commencing at 10:20 AM ET.
Jefferies London Healthcare Conference
Another significant conference will take place on November 20 at the Jefferies London Healthcare Conference. Here, Apogee will present its innovative therapies at 3:30 AM GMT / 10:30 AM ET, highlighting its commitment to addressing high unmet needs in the I&I markets.
Accessing Conference Information
For those interested in following along, Apogee Therapeutics plans to provide live and archived webcasts of the discussions and presentations. Attendees and stakeholders can access these webcasts through the News & Events section on the Apogee Therapeutics website, allowing for a deeper understanding of the company's initiatives and future direction.
About Apogee Therapeutics
Apogee Therapeutics stands at the forefront of medical innovation, focusing on biologics designed for effective treatment options in various inflammatory conditions. With its cutting-edge antibody programs, the company aims to address the limitations faced by existing therapies. These advancements could be particularly transformative for conditions like AD, which are among the largest unmet needs in the I&I markets.
Key Innovations and Pipeline
The standout among its offerings is APG777, which is primarily being developed to tackle atopic dermatitis, one of the most prevalent yet least addressed issues in the market. By leveraging four validated targets, Apogee strives for best-in-class therapies by employing both monotherapies and innovative combinations. This strategy stems from a profound commitment to delivering lasting benefits to patients.
Company Philosophy
Apogee Therapeutics firmly believes that their solutions can significantly alter outcomes for patients who are underserved by current treatments. Their well-articulated strategy and profound expertise position them as pioneers in the biotechnology industry, making a real difference in patients' lives.
Contact Information
Should you have any inquiries, you can reach out to:
Investor Contact:
Noel Kurdi
VP, Investor Relations
Apogee Therapeutics, Inc.
Email: noel.kurdi@apogeetherapeutics.com
Media Contact:
Dan Budwick
1AB
Email: dan@1abmedia.com
Frequently Asked Questions
What is Apogee Therapeutics known for?
Apogee Therapeutics is a biotechnology company focused on developing innovative biologics for treating inflammatory and immunological conditions.
When is Apogee participating in investor conferences?
Apogee will participate in three key conferences in November, including the Guggenheim Healthcare Innovation Conference, Stifel 2024 Healthcare Conference, and Jefferies London Healthcare Conference.
How can I access the conference presentations?
Conference presentations will be accessible through the News & Events section of the Apogee Therapeutics website, including live and archived webcasts.
What is Apogee's most advanced program?
The most advanced program of Apogee Therapeutics is APG777, which targets atopic dermatitis.
Who can I contact for investor inquiries?
You can contact Noel Kurdi, VP of Investor Relations, at noel.kurdi@apogeetherapeutics.com for any investor-related questions.